Skip to main content
SpringerLink
Log in

Systemic Lupus Erythematosus

  • Reference work entry
Pediatric Nephrology

Abstract

Systemic lupus erythematosus (SLE) is a chronic inflammatory disease characterized by highly diverse clinical manifestations and the presence in the serum of a variety of autoantibodies reacting with different cell components. The skin, joints, lungs, heart, kidneys, nervous system, and other organs are involved. The role of autoantibodies in the pathogenesis of the disease is subject to debate. Certain autoantibodies, such as those reacting with cell surface determinants or circulating proteins, are directly responsible for specific clinical manifestations of the disease. The clinical course of the disease is characterized by flares, periods of chronic disease and periods of remissions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 369.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40(9):1725.

    Article  PubMed  CAS  Google Scholar 

  2. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25(11):1271–1277.

    Article  PubMed  CAS  Google Scholar 

  3. Hochberg MC. Systemic lupus erythematosus. Rheum Dis Clin N Am 1990;16(3):617–639.

    CAS  Google Scholar 

  4. Citera G, Wilson WA. Ethnic and geographic perspectives in SLE. Lupus 1993;2(6):351–353.

    Article  PubMed  CAS  Google Scholar 

  5. Symmons DP. Frequency of lupus in people of African origin. Lupus 1995;4(3):176–178.

    Article  PubMed  CAS  Google Scholar 

  6. Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002 19;360(9341):1197–1202.

    Article  PubMed  Google Scholar 

  7. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999;10(2):413–424.

    PubMed  CAS  Google Scholar 

  8. Platt JL, Burke BA, Fish AJ, Kim Y, Michael AF. Systemic lupus erythematosus in the first two decades of life. Am J Kidney Dis 1982;2(1 Suppl 1):212–222.

    PubMed  CAS  Google Scholar 

  9. Carreno L, Lopez-Longo FJ, Monteagudo I, Rodriguez-Mahou M, Bascones M, Gonzalez CM et al. Immunological and clinical differences between juvenile and adult onset of systemic lupus erythematosus. Lupus 1999;8(4):287–292.

    Article  PubMed  CAS  Google Scholar 

  10. Font J, Cervera R, Espinosa G, Pallares L, Ramos-Casals M, Jimenez S et al. Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. Ann Rheum Dis 1998;57(8):456–459.

    Article  PubMed  CAS  Google Scholar 

  11. Rood MJ, ten Cate R, van Suijlekom-Smit LW, den Ouden EJ, Ouwerkerk FE, Breedveld FC et al. Childhood-onset systemic lupus erythematosus: clinical presentation and prognosis in 31 patients. Scand J Rheumatol 1999;28(4):222–226.

    Article  PubMed  CAS  Google Scholar 

  12. Tucker LB, Menon S, Schaller JG, Isenberg DA. Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol 1995;34(9):866–872.

    Article  PubMed  CAS  Google Scholar 

  13. Michel M, Johanet C, Meyer O, Frances C, Wittke F, Michel C et al. Familial lupus erythematosus. Clinical and immunologic features of 125 multiplex families. Medicine 2001;80(3):153–158.

    Article  PubMed  CAS  Google Scholar 

  14. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006;38(5):550–555.

    Article  PubMed  CAS  Google Scholar 

  15. Vang T, Congia M, Macis MD, Musumeci L, Orru V, Zavattari P et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 2005;37(12):1317–1319.

    Article  PubMed  CAS  Google Scholar 

  16. Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier S et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008;358(9):900–909.

    Article  PubMed  CAS  Google Scholar 

  17. Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz HG, Moroy T. Features of systemic lupus erythematosus in DNase1-deficient mice. Nat Genet 2000;25(2):177–181.

    Article  PubMed  CAS  Google Scholar 

  18. Bickerstaff MC, Botto M, Hutchinson WL, Herbert J, Tennent GA, Bybee A et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999;5(6):694–697.

    Article  PubMed  CAS  Google Scholar 

  19. Botto M, Dell’Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998;19(1):56–59.

    Article  PubMed  CAS  Google Scholar 

  20. Hibbs ML, Tarlinton DM, Armes J, Grail D, Hodgson G, Maglitto R et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 1995;83(2):301–311.

    Article  PubMed  CAS  Google Scholar 

  21. Ho CY, Wong CK, Li EK, Tam LS, Lam CW. Expression of cyclin B1 and cyclin dependent kinase inhibitor p21 in lymphocytes in patients with systemic lupus erythematosus. J Rheumatol 2002;29(12):2537–2544.

    PubMed  CAS  Google Scholar 

  22. Liossis SN, Solomou EE, Dimopoulos MA, Panayiotidis P, Mavrikakis MM, Sfikakis PP. B-cell kinase lyn deficiency in patients with systemic lupus erythematosus. J Investig Med 2001;49(2):157–165.

    Article  PubMed  CAS  Google Scholar 

  23. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science (New York, NY) 2001;291(5502):319–322.

    Article  CAS  Google Scholar 

  24. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002;32(4):666–669.

    Article  PubMed  CAS  Google Scholar 

  25. Balomenos D, Martin-Caballero J, Garcia MI, Prieto I, Flores JM, Serrano M et al. The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development. Nat Med 2000;6(2):171–176.

    Article  PubMed  CAS  Google Scholar 

  26. Sorensen IJ, Holm Nielsen E, Schroder L, Voss A, Horvath L, Svehag SE. Complexes of serum amyloid P component and DNA in serum from healthy individuals and systemic lupus erythematosus patients. J Clin Immunol 2000;20(6):408–415.

    Article  PubMed  CAS  Google Scholar 

  27. Walport MJ, Davies KA, Botto M. C1q and systemic lupus erythematosus. Immunobiology 1998;199(2):265–285.

    Article  PubMed  CAS  Google Scholar 

  28. Yasutomo K, Horiuchi T, Kagami S, Tsukamoto H, Hashimura C, Urushihara M et al. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet 2001;28(4):313–314.

    Article  PubMed  CAS  Google Scholar 

  29. Aitman TJ, Dong R, Vyse TJ, Norsworthy PJ, Johnson MD, Smith J et al. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 2006;439(7078):851–855.

    Article  PubMed  CAS  Google Scholar 

  30. Fanciulli M, Norsworthy PJ, Petretto E, Dong R, Harper L, Kamesh L et al. FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat Genet 2007;39(6):721–723.

    Article  PubMed  CAS  Google Scholar 

  31. James JA, Neas BR, Moser KL, Hall T, Bruner GR, Sestak AL et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 2001;44(5):1122–1126.

    Article  PubMed  CAS  Google Scholar 

  32. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 16 2003;349(16):1526–1533.

    Article  PubMed  CAS  Google Scholar 

  33. McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med 2005;11(1):85–89.

    Article  PubMed  CAS  Google Scholar 

  34. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994;179(4):1317–30.

    Article  PubMed  CAS  Google Scholar 

  35. Hieronymus T, Grotsch P, Blank N, Grunke M, Capraru D, Geiler T et al. Chlorpromazine induces apoptosis in activated human lymphoblasts: a mechanism supporting the induction of drug-induced lupus erythematosus? Arthritis Rheum 2000;43(9):1994–2004.

    Article  PubMed  CAS  Google Scholar 

  36. Lahita RG. Sex hormones and systemic lupus erythematosus. Rheum Dis Clin N Am 2000;26(4):951–968.

    Article  CAS  Google Scholar 

  37. McMurray RW. Sex hormones in the pathogenesis of systemic lupus erythematosus. Front Biosci 2001;6:E193–E206.

    Article  PubMed  CAS  Google Scholar 

  38. Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS. Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case-control study. Arthritis Rheum 2002;46(7):1830–1839.

    Article  PubMed  CAS  Google Scholar 

  39. Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev 2001;1(2):147–153.

    Article  CAS  Google Scholar 

  40. Kumar KR, Li L, Yan M, Bhaskarabhatla M, Mobley AB, Nguyen C et al. Regulation of B cell tolerance by the lupus susceptibility gene Ly108. Science (New York, NY) 2006;312(5780):1665–1669.

    Article  CAS  Google Scholar 

  41. McGaha TL, Sorrentino B, Ravetch JV. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science (New York, NY) 2005;307(5709):590–593.

    Article  CAS  Google Scholar 

  42. Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4+ CD25high T regulatory cell function in patients with active systemic lup us erythematosus. J Immunol 2007;178(4):2579–2588.

    PubMed  CAS  Google Scholar 

  43. Nash JT, Taylor PR, Botto M, Norsworthy PJ, Davies KA, Walport MJ. Immune complex processing in C1q-deficient mice. Clin Exp Immunol 2001;123(2):196–202.

    Article  PubMed  CAS  Google Scholar 

  44. Prodeus AP, Goerg S, Shen LM, Pozdnyakova OO, Chu L, Alicot EM et al. A critical role for complement in maintenance of self-tolerance. Immunity 1998;9(5):721–731.

    Article  PubMed  CAS  Google Scholar 

  45. Scott RS, McMahon EJ, Pop SM, Reap EA, Caricchio R, Cohen PL et al. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 2001;411(6834):207–211.

    Article  PubMed  CAS  Google Scholar 

  46. Janeway CA, Jr., Bottomly K. Signals and signs for lymphocyte responses. Cell 1994;76(2):275–285.

    Article  PubMed  CAS  Google Scholar 

  47. Amoura Z, Koutouzov S, Piette JC. The role of nucleosomes in lupus. Curr Opin Rheum 2000;12(5):369–373.

    Article  CAS  Google Scholar 

  48. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science (New York, NY) 2001;294(5546):1540–1543.

    Article  CAS  Google Scholar 

  49. Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 2000;76:227–324.

    Article  PubMed  CAS  Google Scholar 

  50. Trouw LA, Blom AM, Gasque P. Role of complement and complement regulators in the removal of apoptotic cells. Mol Immunol 2008;45(5):1199–1207.

    Article  PubMed  CAS  Google Scholar 

  51. Rosenberg AM. Systemic lupus erythematosus in children. Springer Semin Immunopathol 1994;16(2–3):261–279.

    PubMed  CAS  Google Scholar 

  52. Bader-Meunier B, Armengaud JB, Haddad E, Salomon R, Deschenes G, Kone-Paut I et al. Initial presentation of childhood-onset systemic lupus erythematosus: a French multicenter study. J Pediatr 2005;146(5):648–653.

    Article  PubMed  CAS  Google Scholar 

  53. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine 1993;72(2):113–124.

    Article  PubMed  CAS  Google Scholar 

  54. Nived O, Johansen PB, Sturfelt G. Standardized ultraviolet-A exposure provokes skin reaction in systemic lupus erythematosus. Lupus 1993;2(4):247–250.

    Article  PubMed  CAS  Google Scholar 

  55. Duffy KN, Duffy CM, Gladman DD. Infection and disease activity in systemic lupus erythematosus: a review of hospitalized patients. J Rheumatol 1991;18(8):1180–1184.

    PubMed  CAS  Google Scholar 

  56. Adams SG, Jr., Dammers PM, Saia TL, Brantley PJ, Gaydos GR. Stress, depression, and anxiety predict average symptom severity and daily symptom fluctuation in systemic lupus erythematosus. J Behav Med 1994;17(5):459–477.

    Article  PubMed  Google Scholar 

  57. Pistiner M, Wallace DJ, Nessim S, Metzger AL, Klinenberg JR. Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 1991;21(1):55–64.

    Article  PubMed  CAS  Google Scholar 

  58. Werth VP. Clinical manifestations of cutaneous lupus erythematosus. Autoimmun Rev 2005;4(5):296–302.

    Article  PubMed  Google Scholar 

  59. Yeh TT, Yang YH, Lin YT, Lu CS, Chiang BL. Cardiopulmonary involvement in pediatric systemic lupus erythematosus: a twenty-year retrospective analysis. J Microbiol Immunol Infect 2007;40(6):525–531.

    PubMed  Google Scholar 

  60. Memet B, Ginzler EM. Pulmonary manifestations of systemic lupus erythematosus. Semin Respir Crit Care Med 2007;28(4):441–450.

    Article  PubMed  Google Scholar 

  61. Pan TL, Thumboo J, Boey ML. Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus 2000;9(5):338–342.

    Article  PubMed  CAS  Google Scholar 

  62. Farzaneh-Far A, Roman MJ, Lockshin MD, Devereux RB, Paget SA, Crow MK et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum 2006;54(12):3918–25.

    Article  PubMed  CAS  Google Scholar 

  63. Leung WH, Wong KL, Lau CP, Wong CK, Liu HW. Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med 1990;89(4):411–419.

    Article  PubMed  CAS  Google Scholar 

  64. Quintero-Del-Rio AI, Van M. Neurologic symptoms in children with systemic lupus erythematosus. J Child Neurol 2000;15(12):803–807.

    Article  PubMed  CAS  Google Scholar 

  65. Steinlin MI, Blaser SI, Gilday DL, Eddy AA, Logan WJ, Laxer RM et al. Neurologic manifestations of pediatric systemic lupus erythematosus. Pediatr Neurol 1995;13(3):191–197.

    Article  PubMed  CAS  Google Scholar 

  66. Benseler SM, Silverman ED. Neuropsychiatric involvement in pediatric systemic lupus erythematosus. Lupus 2007;16(8):564–571.

    Article  PubMed  CAS  Google Scholar 

  67. Denburg SD, Carbotte RM, Denburg JA. Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus. Arthritis Rheum Sep1994;37(9):1311–1320.

    Article  CAS  Google Scholar 

  68. Yu HH, Lee JH, Wang LC, Yang YH, Chiang BL. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: a 20-year study. Lupus 2006;15(10):651–657.

    Article  PubMed  CAS  Google Scholar 

  69. Iverson GL, Anderson KW. The etiology of psychiatric symptoms in patients with systemic lupus erythematosus. Scand J Rheumatol 1994;23(5):277–282.

    Article  PubMed  CAS  Google Scholar 

  70. Miguel EC, Pereira RM, Pereira CA, Baer L, Gomes RE, de Sa LC et al. Psychiatric manifestations of systemic lupus erythematosus: clinical features, symptoms, and signs of central nervous system activity in 43 patients. Medicine 1994;73(4):224–232.

    Article  PubMed  CAS  Google Scholar 

  71. Nery FG, Borba EF, Hatch JP, Soares JC, Bonfa E, Neto FL. Major depressive disorder and disease activity in systemic lupus erythematosus. Compr Psychiatry 2007;48(1):14–19.

    Article  PubMed  Google Scholar 

  72. Appenzeller S, Pike GB, Clarke AE. Magnetic resonance imaging in the evaluation of central nervous system manifestations in systemic lupus erythematosus. Clin Rev Allergy Immunol 2007;34:361–366.

    Article  Google Scholar 

  73. Karassa FB, Ioannidis JP, Touloumi G, Boki KA, Moutsopoulos HM. Risk factors for central nervous system involvement in systemic lupus erythematosus. QJM 2000;93(3):169–174.

    Article  PubMed  CAS  Google Scholar 

  74. Muscal E, Myones BL. The role of autoantibodies in pediatric neuropsychiatric systemic lupus erythematosus. Autoimmun Rev 2007;6(4):215–217.

    Article  PubMed  Google Scholar 

  75. Peponis V, Kyttaris VC, Tyradellis C, Vergados I, Sitaras NM. Ocular manifestations of systemic lupus erythematosus: a clinical review. Lupus 2006;15(1):3–12.

    Article  PubMed  CAS  Google Scholar 

  76. Beyan E, Beyan C, Turan M. Hematological presentation in systemic lupus erythematosus and its relationship with disease activity. Hematology (Amsterdam, Netherlands) 2007;12(3):257–261.

    CAS  Google Scholar 

  77. Bertolaccini ML, Hughes GR. Antiphospholipid antibody testing: which are most useful for diagnosis? Rheum Dis Clin N Am 2006;32(3):455–463.

    Article  Google Scholar 

  78. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346(10):752–763.

    Article  PubMed  CAS  Google Scholar 

  79. Descloux E, Durieu I, Cochat P, Vital Durand D, Ninet J, Fabien N et al. Paediatric systemic lupus erythematosus: prognostic impact of antiphospholipid antibodies. Rheumatology (Oxford, England)2008;47(2):183–187.

    Article  CAS  Google Scholar 

  80. Fischer MJ, Rauch J, Levine JS. The antiphospholipid syndrome. Semin Nephrol 2007;27(1):35–46.

    Article  PubMed  CAS  Google Scholar 

  81. Lee T, Scheven E, von Sandborg C. Systemic lupus erythematosus and antiphospholipid syndrome in children and adolescents. Curr Opin Rheumatol 2001;13(5):415–421.

    Article  PubMed  CAS  Google Scholar 

  82. Black A. Antiphospholipid syndrome: an overview. Clin Lab Sci 2006 Summer;19(3):144–147.

    PubMed  Google Scholar 

  83. Daugas E, Nochy D, Huong DL, Duhaut P, Beaufils H, Caudwell V et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol 2002;13(1):42–52.

    PubMed  Google Scholar 

  84. Berube C, Mitchell L, Silverman E, David M, Saint Cyr C, Laxer R  et al. The relationship of antiphospholipid antibodies to thromboembolic events in pediatric patients with systemic lupus erythematosus: a cross-sectional study. Pediatr Res 1998;44(3):351–356.

    Article  PubMed  CAS  Google Scholar 

  85. Massengill SF, Hedrick C, Ayoub EM, Sleasman JW, Kao KJ. Antiphospholipid antibodies in pediatric lupus nephritis. Am J Kidney Dis 1997;29(3):355–361.

    Article  PubMed  CAS  Google Scholar 

  86. Mihailova D, Grigorova R, Vassileva B, Mladenova G, Ivanova N, Stephanov S et al. Autoimmune thyroid disorders in juvenile chronic arthritis and systemic lupus erythematosus. Adv Exp Med Biol 1999;455:55–60.

    Article  PubMed  CAS  Google Scholar 

  87. Mok CC, Wong RW. Pregnancy in systemic lupus erythematosus. Postgrad Med J 2001;77(905):157–165.

    Article  PubMed  CAS  Google Scholar 

  88. Hallegua DS, Wallace DJ. Gastrointestinal manifestations of systemic lupus erythematosus. Curr Opin Rheumatol 2000;12(5):379–385.

    Article  PubMed  CAS  Google Scholar 

  89. Kalaaji M, Fenton KA, Mortensen ES, Olsen R, Sturfelt G, Alm P et al. Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int 2007;71(7):664–672.

    Article  PubMed  CAS  Google Scholar 

  90. Kalaaji M, Mortensen E, Jorgensen L, Olsen R, Rekvig OP. Nephritogenic lupus antibodies recognize glomerular basement membrane-associated chromatin fragments released from apoptotic intraglomerular cells. Am J Pathol 2006;168(6):1779–1792.

    Article  PubMed  CAS  Google Scholar 

  91. Deocharan B, Qing X, Lichauco J, Putterman C. Alpha-actinin is a cross-reactive renal target for pathogenic anti-DNA antibodies. J Immunol 2002;168(6):3072–3078.

    PubMed  CAS  Google Scholar 

  92. Korb LC, Ahearn JM. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J Immunol 1997;158(10):4525–4528.

    PubMed  CAS  Google Scholar 

  93. Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science (New York, NY) 1998;279(5353):1052–1054.

    Article  CAS  Google Scholar 

  94. Seligman VA, Suarez C, Lum R, Inda SE, Lin D, Li H et al. The Fcgamma receptor IIIA-158F allele is a major risk factor for the development of lupus nephritis among Caucasians but not non-Caucasians. Arthritis Rheum 2001;44(3):618–625.

    Article  PubMed  CAS  Google Scholar 

  95. Karassa FB, Trikalinos TA, Ioannidis JP. Role of the Fcgamma receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Arthritis Rheum 2002;46(6):1563–1571.

    Article  PubMed  CAS  Google Scholar 

  96. Schiffer L, Bethunaickan R, Ramanujam M, Huang W, Schiffer M, Tao H et al. Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol 2008;180(3):1938–1947.

    PubMed  CAS  Google Scholar 

  97. Ponticelli C, Moroni G. Renal biopsy in lupus nephritis–what for, when and how often? Nephrol Dial Transplant 1998;13(10):2452–2454.

    Article  PubMed  CAS  Google Scholar 

  98. Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15(2):241–250.

    Article  PubMed  Google Scholar 

  99. Schwartz MM. The pathology of lupus nephritis. Semin Nephrol 2007;27(1):22–34.

    Article  PubMed  CAS  Google Scholar 

  100. Marks SD, Sebire NJ, Pilkington C, Tullus K. Clinicopathological correlations of paediatric lupus nephritis. Pediatr Nephrol (Berlin, Germany) 2007;22(1):77–83.

    Article  Google Scholar 

  101. Appel GB, Cohen DJ, Pirani CL, Meltzer JI, Estes D. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med 1987;83(5):877–885.

    Article  PubMed  CAS  Google Scholar 

  102. Baldwin DS. Clinical usefulness of the morphological classification of lupus nephritis. Am J Kidney Dis Jul 1982;2(1 Suppl 1):142–149.

    PubMed  CAS  Google Scholar 

  103. Lee HS, Mujais SK, Kasinath BS, Spargo BH, Katz AI. Course of renal pathology in patients with systemic lupus erythematosus. Am J Med 1984;77(4):612–620.

    Article  PubMed  CAS  Google Scholar 

  104. Schwartz MM, Kawala KS, Corwin HL, Lewis EJ. The prognosis of segmental glomerulonephritis in systemic lupus erythematosus. Kidney Int 1987;32(2):274–279.

    Article  PubMed  CAS  Google Scholar 

  105. Morel-Maroger L, Mery JP, Droz D, Godin M, Verroust P, Kourilsky O et al. The course of lupus nephritis: contribution of serial renal biopsies. Adv Nephrol Necker Hosp 1976;6:79–118.

    PubMed  CAS  Google Scholar 

  106. Austin HA, 3rd, Muenz LR, Joyce KM, Antonovych TA, Kullick ME, Klippel JH et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 1983 Sep;75(3):382–391.

    Article  PubMed  Google Scholar 

  107. Najafi CC, Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 2001;59(6):2156–2163.

    PubMed  CAS  Google Scholar 

  108. Schwartz MM, Lan SP, Bernstein J, Hill GS, Holley K, Lewis EJ. Role of pathology indices in the management of severe lupus glomerulonephritis. Lupus Nephritis Collaborative Study Group. Kidney Int 1992;42(3):743–748.

    Article  PubMed  CAS  Google Scholar 

  109. Hill GS, Delahousse M, Nochy D, Remy P, Mignon F, Mery JP et al. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int 2001;59(1):304–316.

    Article  PubMed  CAS  Google Scholar 

  110. Lupus nephritis: prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Am J Kidney Dis 1992;19(5):473–479.

    Google Scholar 

  111. Appel GB, Valeri A. The course and treatment of lupus nephritis. Annu Rev Med 1994;45:525–537.

    Article  PubMed  CAS  Google Scholar 

  112. Austin HA, III, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994;45(2):544–550.

    Article  PubMed  Google Scholar 

  113. Austin HA, III, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int Apr 1984;25(4):689–695.

    Article  PubMed  Google Scholar 

  114. Donadio JV, Jr., Hart GM, Bergstralh EJ, Holley KE. Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus 1995;4(2):109–115.

    Article  PubMed  Google Scholar 

  115. Esdaile JM, Levinton C, Federgreen W, Hayslett JP, Kashgarian M. The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: a study of 87 patients and review of the literature. QJM 1989;72(269):779–833.

    PubMed  CAS  Google Scholar 

  116. Austin HA, III, Boumpas DT, Vaughan EM, Balow JE. High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 1995;10(9):1620–1628.

    PubMed  Google Scholar 

  117. Baqi N, Moazami S, Singh A, Ahmad H, Balachandra S, Tejani A. Lupus nephritis in children: a longitudinal study of prognostic factors and therapy. J Am Soc Nephrol 1996;7(6):924–929.

    PubMed  CAS  Google Scholar 

  118. Conlon PJ, Fischer CA, Levesque MC, Smith SR, St Clair EW, Allen NB et al. Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients withproliferative lupus nephritis. Clin Nephrol 1996;46(3):170–175.

    PubMed  CAS  Google Scholar 

  119. Iseki K, Miyasato F, Oura T, Uehara H, Nishime K, Fukiyama K. An epidemiologic analysis of end-stage lupus nephritis. Am J Kidney Dis 1994;23(4):547–554.

    PubMed  CAS  Google Scholar 

  120. Moroni G, Quaglini S, Maccario M, Banfi G, Ponticelli C. “Nephritic flares” are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996;50(6):2047–2053.

    Article  PubMed  CAS  Google Scholar 

  121. Dooley MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 1997;51(4):1188–1195.

    Article  PubMed  CAS  Google Scholar 

  122. Levey AS, Lan SP, Corwin HL, Kasinath BS, Lachin J, Neilson EG et al. Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide. Ann Intern Med 1992;116(2):114–123.

    PubMed  CAS  Google Scholar 

  123. Magil AB, Puterman ML, Ballon HS, Chan V, Lirenman DS, Rae A et al. Prognostic factors in diffuse proliferative lupus glomerulonephritis. Kidney Int Oct 1988;34(4):511–517.

    Article  PubMed  CAS  Google Scholar 

  124. McCurdy DK, Lehman TJ, Bernstein B, Hanson V, King KK, Nadorra R et al. Lupus nephritis: prognostic factors in children. Pediatrics 1992;89(2):240–246.

    PubMed  CAS  Google Scholar 

  125. Ginzler EM, Diamond HS, Weiner M, Schlesinger M, Fries JF, Wasner C et al. A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum 1982;25(6):601–611.

    Article  PubMed  CAS  Google Scholar 

  126. Esdaile JM, Joseph L, MacKenzie T, Kashgarian M, Hayslett JP. The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rheumatol 1994;21(11):2046–2051.

    PubMed  CAS  Google Scholar 

  127. Lim CS, Chin HJ, Jung YC, Kim YS, Ahn C, Han JS et al. Prognostic factors of diffuse proliferative lupus nephritis. Clin Nephrol 1999;52(3):139–147.

    PubMed  CAS  Google Scholar 

  128. Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 2004;50(8):2559–2568.

    Article  PubMed  CAS  Google Scholar 

  129. Moroni G, Gallelli B, Quaglini S, Banfi G, Rivolta E, Messa P et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant 2006;21(6):1541–1548.

    Article  PubMed  CAS  Google Scholar 

  130. Barber CE, Geldenhuys L, Hanly JG. Sustained remission of lupus nephritis. Lupus 2006;15(2):94–101.

    Article  PubMed  CAS  Google Scholar 

  131. Contreras G, Lenz O, Pardo V, Borja E, Cely C, Iqbal K et al. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int 2006;69(10):1846–1851.

    Article  PubMed  CAS  Google Scholar 

  132. Korbet SM, Schwartz MM, Evans J, Lewis EJ. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 2007;18(1):244–254.

    Article  PubMed  Google Scholar 

  133. Cameron JS. Lupus nephritis in childhood and adolescence. Pediatr Nephrol (Berlin, Germany) 1994;8(2):230–249.

    Article  CAS  Google Scholar 

  134. Yang LY, Chen WP, Lin CY. Lupus nephritis in children–a review of 167 patients. Pediatrics 1994;94(3):335–340.

    PubMed  CAS  Google Scholar 

  135. Emre S, Bilge I, Sirin A, Kilicaslan I, Nayir A, Oktem F et al. Lupus nephritis in children: prognostic significance of clinicopathological findings. Nephron 2001;87(2):118–126.

    Article  PubMed  CAS  Google Scholar 

  136. Pasquali S, Banfi G, Zucchelli A, Moroni G, Ponticelli C, Zucchelli P. Lupus membranous nephropathy: long-term outcome. Clin Nephrol 1993;39(4):175–182.

    PubMed  CAS  Google Scholar 

  137. Sloan RP, Schwartz MM, Korbet SM, Borok RZ. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group. J Am Soc Nephrol 1996;7(2):299–305.

    PubMed  CAS  Google Scholar 

  138. Nathanson S, Salomon R, Ranchin B, Macher MA, Lavocat MP, Krier MJ et al. Prognosis of lupus membranous nephropathy in children. Pediatr Nephrol (Berlin, Germany) 2006;21(8):1113–1116.

    Article  Google Scholar 

  139. Pisetsky DS. Anti-DNA and autoantibodies. Curr Opin Rheumatol 2000;12(5):364–368.

    Article  PubMed  CAS  Google Scholar 

  140. von Muhlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995;24(5):323–358.

    Article  PubMed  CAS  Google Scholar 

  141. Eaton RB, Schnneider G, Schur PH. Enzyme immunoassay for antibodies to native DNA. Specificity and quality of antibodies. Arthritis Rheum 1983;26(1):52–62.

    Article  PubMed  CAS  Google Scholar 

  142. Hahn BH. Antibodies to DNA. N Engl J Med 1998;338(19):1359–1368.

    Article  PubMed  CAS  Google Scholar 

  143. Smeenk R, Brinkman K, van den Brink H, Termaat RM, Berden J, Nossent H et al. Antibodies to DNA in patients with systemic lupus erythematosus. Their role in the diagnosis, the follow-up and the pathogenesis of the disease. Clin Rheumatol 1990;9(1 Suppl 1):100–110.

    Article  PubMed  CAS  Google Scholar 

  144. ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990;33(5):634–643.

    Article  PubMed  CAS  Google Scholar 

  145. Tan EM, Kunkel HG. Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus. J Immunol 1966;96(3):464–471.

    PubMed  CAS  Google Scholar 

  146. Munves EF, Schur PH. Antibodies to Sm and RNP. Prognosticators of disease involvement. Arthritis Rheum 1983;26(7):848–853.

    Article  PubMed  CAS  Google Scholar 

  147. Benito-Garcia E, Schur PH, Lahita R. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests. Arthritis Rheum 2004;51(6):1030–1044.

    Article  PubMed  CAS  Google Scholar 

  148. Siegert CE, Daha MR, Tseng CM, Coremans IE, van Es LA, Breedveld FC. Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. Ann Rheum Dis 1993;52(12):851–856.

    Article  PubMed  CAS  Google Scholar 

  149. Siegert CE, Kazatchkine MD, Sjoholm A, Wurzner R, Loos M, Daha MR. Autoantibodies against C1q: view on clinical relevance and pathogenic role. Clin Exp Immunol 1999;116(1):4–8.

    Article  PubMed  CAS  Google Scholar 

  150. Cardinali C, Caproni M, Fabbri P. The utility of the lupus band test on sun-protected non-lesional skin for the diagnosis of systemic lupus erythematosus. Clin Exp Rheumatol 1999;17(4):427–432.

    PubMed  CAS  Google Scholar 

  151. Spronk PE, Limburg PC, Kallenberg CG. Serological markers of disease activity in systemic lupus erythematosus. Lupus 1995;4(2):86–94.

    Article  PubMed  CAS  Google Scholar 

  152. Fritzler MJ. Drugs recently associated with lupus syndromes. Lupus 1994;3(6):455–459.

    Article  PubMed  CAS  Google Scholar 

  153. Hess E. Drug-related lupus. N Engl J Med 1988;318(22):1460–1462.

    Article  PubMed  CAS  Google Scholar 

  154. Grant DM, Morike K, Eichelbaum M, Meyer UA. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest 1990;85(3):968–972.

    Article  PubMed  CAS  Google Scholar 

  155. Rubin RL, Bell SA, Burlingame RW. Autoantibodies associated with lupus induced by diverse drugs target a similar epitope in the (H2A-H2B)-DNA complex. J Clin Invest 1992;90(1):165–173.

    Article  PubMed  CAS  Google Scholar 

  156. Julkunen H, Kurki P, Kaaja R, Heikkila R, Immonen I, Chan EK et al. Isolated congenital heart block. Long-term outcome of mothers and characterization of the immune response to SS-A/Ro and to SS-B/La. Arthritis Rheum 1993;36(11):1588–1598.

    Article  PubMed  CAS  Google Scholar 

  157. Buyon JP, Kim MY, Copel JA, Friedman DM. Anti-Ro/SSA antibodies and congenital heart block: necessary but not sufficient. Arthritis Rheum 2001;44(8):1723–1727.

    Article  PubMed  CAS  Google Scholar 

  158. Lee LA. Neonatal lupus: clinical features, therapy, and pathogenesis. Curr Rheumatol Rep 2001;3(5):391–395.

    Article  PubMed  CAS  Google Scholar 

  159. Zimmerman R, Radhakrishnan J, Valeri A, Appel G. Advances in the treatment of lupus nephritis. Annu Rev Med 2001;52:63–78.

    Article  PubMed  CAS  Google Scholar 

  160. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000;35(5):904–914.

    Article  PubMed  CAS  Google Scholar 

  161. El Hachmi M, Jadoul M, Lefebvre C, Depresseux G, Houssiau FA. Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. Lupus 2003;12(9):692–696.

    Article  PubMed  CAS  Google Scholar 

  162. Barron KS, Person DA, Brewer EJ, Jr., Beale MG, Robson AM. Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis. J Pediatr 1982;101(1):137–141.

    Article  PubMed  CAS  Google Scholar 

  163. Cathcart ES, Idelson BA, Scheinberg MA, Couser WG. Beneficial effects of methylprednisolone “pulse” therapy in diffuse proliferative lupus nephritis. Lancet 1976;1(7952):163–166.

    Article  PubMed  CAS  Google Scholar 

  164. Kimberly RP, Lockshin MD, Sherman RL, McDougal JS, Inman RD, Christian CL. High-dose intravenous methylprednisolone pulse therapy in systemic lupus erythematosus. Am J Med 1981;70(4):817–824.

    Article  PubMed  CAS  Google Scholar 

  165. Austin HA, III, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314(10):614–619.

    Article  PubMed  Google Scholar 

  166. Donadio JV, Jr., Holley KE, Ferguson RH, Ilstrup DM. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 1978;299(21):1151–1155.

    Article  PubMed  Google Scholar 

  167. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991;34(8):945–950.

    Article  PubMed  CAS  Google Scholar 

  168. Boumpas DT, Austin HA, 3rd, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340(8822):741–745.

    Article  PubMed  CAS  Google Scholar 

  169. Gourley MF, Austin HA, 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996;125(7):5495–57.

    Google Scholar 

  170. Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2004;43(2):197–208.

    Article  PubMed  CAS  Google Scholar 

  171. Ognenovski VM, Marder W, Somers EC, Johnston CM, Farrehi JG, Selvaggi SM et al. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol 2004;31(9):1763–1767.

    PubMed  CAS  Google Scholar 

  172. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46(8):2121–2131.

    Article  PubMed  CAS  Google Scholar 

  173. Houssiau F. Thirty years of cyclophosphamide: assessing the evidence. Lupus 2007;16(3):212–216.

    PubMed  CAS  Google Scholar 

  174. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004;50(12):3934–3940.

    Article  PubMed  Google Scholar 

  175. Niaudet P. Treatment of lupus nephritis in children. Pediatr Nephrol (Berlin, Germany) 2000;14(2):158–166.

    Article  CAS  Google Scholar 

  176. Lehman TJ, Sherry DD, Wagner-Weiner L, McCurdy DK, Emery HM, Magilavy DB et al. Intermittent intravenous cyclophosphamide therapy for lupus nephritis. J Pediatr 1989;114(6):1055–1060.

    Article  PubMed  CAS  Google Scholar 

  177. Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int. 2006;70(4):732–742.

    Article  PubMed  CAS  Google Scholar 

  178. Van Bruggen MC, Walgreen B, Rijke TP, Berden JH. Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol 1998;9(8):1407–1415.

    PubMed  CAS  Google Scholar 

  179. Zoja C, Benigni A, Noris M, Corna D, Casiraghi F, Pagnoncelli M et al. Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. Kidney international 2001;60(2):653–663.

    Article  PubMed  CAS  Google Scholar 

  180. Buratti S, Szer IS, Spencer CH, Bartosh S, Reiff A. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 2001;28(9):2103–2108.

    PubMed  CAS  Google Scholar 

  181. Dooley MA, Cosio FG, Nachman PH, Falkenhain ME, Hogan SL, Falk RJ et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999;10(4):833–839.

    PubMed  CAS  Google Scholar 

  182. Glicklich D, Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis 1998;32(2):318–322.

    Article  PubMed  CAS  Google Scholar 

  183. Kingdon EJ, McLean AG, Psimenou E, Davenport A, Powis SH, Sweny P et al. The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 2001;10(9):606–611.

    Article  PubMed  CAS  Google Scholar 

  184. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343(16):1156–1162.

    Article  PubMed  CAS  Google Scholar 

  185. Ong LM, Hooi LS, Lim TO, Goh BL, Ahmad G, Ghazalli R et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 2005;10(5):504–510.

    Article  CAS  Google Scholar 

  186. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353(21):2219–2228.

    Article  PubMed  CAS  Google Scholar 

  187. Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2007;2(5):968–975.

    Article  PubMed  CAS  Google Scholar 

  188. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 1992;326(21):1373–1379.

    Article  PubMed  CAS  Google Scholar 

  189. Euler HH, Guillevin L. Plasmapheresis and subsequent pulse cyclophosphamide in severe systemic lupus erythematosus. An interim report of the Lupus Plasmapheresis Study Group. Annales de medecine interne 1994;145(5):296–302.

    PubMed  CAS  Google Scholar 

  190. Jordan SC, Ho W, Ettenger R, Salusky IB, Fine RN. Plasma exchange improves the glomerulonephritis of systemic lupus erythematosus in selected pediatric patients. Pediatric nephrology (Berlin, Germany) 1987;1(3):276–280.

    Article  CAS  Google Scholar 

  191. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O’Nan P et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350(10):971–980.

    Article  PubMed  CAS  Google Scholar 

  192. Contreras G, Tozman E, Nahar N, Metz D. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 2005;14 Suppl 1:s33–s38.

    Article  PubMed  CAS  Google Scholar 

  193. Grootscholten C, Berden JH. Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible? Nephrol Dial Transplant 2006;21(6):1465–1469.

    Article  PubMed  Google Scholar 

  194. Hebert LA, Dillon JJ, Middendorf DF, Lewis EJ, Peter JB. Relationship between appearance of urinary red blood cell/white blood cell casts and the onset of renal relapse in systemic lupus erythematosus. Am J Kidney Dis 1995;26(3):432–438.

    Article  PubMed  CAS  Google Scholar 

  195. LeBlanc BA, Urowitz MB, Gladman OD. Serologically active, clinically quiescent systemic lupus erythematosus longterm followup. J Rheumatol 1994;21(1):174–175.

    PubMed  CAS  Google Scholar 

  196. Ponticelli C. Treatment of lupus nephritis the advantages of a flexible approach. Nephrol Dial Transplant 1997;12(10):2057–2059.

    Article  PubMed  CAS  Google Scholar 

  197. Balow JE, Austin HA, 3rd. Therapy of membranous nephropathy in systemic lupus erythematosus. Semin Nephrol 2003;23(4):386–391.

    Article  PubMed  CAS  Google Scholar 

  198. Moroni G, Maccario M, Banfi G, Quaglini S, Ponticelli C. Treatment of membranous lupus nephritis. Am J Kidney Dis 1998;31(4):681–686.

    Article  PubMed  CAS  Google Scholar 

  199. Radhakrishnan J, Kunis CL, D’Agati V, Appel GB. Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 1994;42(3):147–154.

    PubMed  CAS  Google Scholar 

  200. Kanda H, Kubo K, Tateishi S, Sato K, Yonezumi A, Yamamoto K et al. Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. Lupus 2005;14(4):288–292.

    Article  PubMed  CAS  Google Scholar 

  201. Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005;52(2):501–513.

    Article  PubMed  CAS  Google Scholar 

  202. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46(10):2673–2677.

    Article  PubMed  Google Scholar 

  203. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50(8):2580–2589.

    Article  PubMed  CAS  Google Scholar 

  204. Marks SD, Tullus K. Successful outcomes with rituximab therapy for refractory childhood systemic lupus erythematosus. Pediatr Nephrol (Berlin, Germany) 2006;21(4):598–599.

    Article  Google Scholar 

  205. Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005;17(5):550–557.

    Article  PubMed  CAS  Google Scholar 

  206. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006;54(9):2970–2982.

    Article  PubMed  CAS  Google Scholar 

  207. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, Portales-Perez D, Baranda L, Abud-Mendoza C et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006;8(3):R83.

    Article  PubMed  CAS  Google Scholar 

  208. Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007;56(4):1263–1272.

    Article  PubMed  CAS  Google Scholar 

  209. Willems M, Haddad E, Niaudet P, Kone-Paut I, Bensman A, Cochat P et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 2006;148(5):623–627.

    Article  PubMed  CAS  Google Scholar 

  210. Boletis JN, Ioannidis JP, Boki KA, Moutsopoulos HM. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 1999;354(9178):569–570.

    Article  PubMed  CAS  Google Scholar 

  211. Lin CY, Hsu HC, Chiang H. Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin. Nephron 1989;53(4):303–310.

    Article  PubMed  CAS  Google Scholar 

  212. Zandman-Goddard G, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol 2005;29(3):219–228.

    Article  PubMed  CAS  Google Scholar 

  213. Furie RA, Cash JM, Cronin ME, Katz RS, Weisman MH, Aranow C et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol 2001;28(2):257–265.

    PubMed  CAS  Google Scholar 

  214. Alarcon-Segovia D, Tumlin JA, Furie RA, McKay JD, Cardiel MH, Strand V et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003;48(2):442–454.

    Article  PubMed  CAS  Google Scholar 

  215. Kalled SL, Cutler AH, Datta SK, Thomas DW. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J Immunol 1998;160(5):2158–2165.

    PubMed  CAS  Google Scholar 

  216. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000;6(2):114.

    Article  CAS  Google Scholar 

  217. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349(20):1907–0915.

    Article  PubMed  CAS  Google Scholar 

  218. Davidson A, Diamond B, Wofsy D, Daikh D. Block and tackle: CTLA4Ig takes on lupus. Lupus 2005;14(3):197–203.

    Article  PubMed  CAS  Google Scholar 

  219. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003;48(3):719–727.

    Article  PubMed  CAS  Google Scholar 

  220. Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol 2001;13(5):345–351.

    Article  PubMed  CAS  Google Scholar 

  221. Petri M. Infection in systemic lupus erythematosus. Rheum Dis Clin North Am 1998;24(2):423–456.

    Article  PubMed  CAS  Google Scholar 

  222. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine 2003;82(5):299–308.

    Article  PubMed  Google Scholar 

  223. Ginzler E, Diamond H, Kaplan D, Weiner M, Schlesinger M, Seleznick M. Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum 1978;21(1):37–44.

    Article  PubMed  CAS  Google Scholar 

  224. Paton NI, Cheong IK, Kong NC, Segasothy M. Risk factors for infection in Malaysian patients with systemic lupus erythematosus. QJM 1996;89(7):531–538.

    Article  PubMed  CAS  Google Scholar 

  225. Pryor BD, Bologna SG, Kahl LE. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 1996;39(9):1475–1482.

    Article  PubMed  CAS  Google Scholar 

  226. Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM 1999;92(4):211–218.

    Article  PubMed  CAS  Google Scholar 

  227. Farhey Y, Hess EV. Accelerated atherosclerosis and coronary disease in SLE. Lupus 1997;6(7):572–577.

    Article  PubMed  CAS  Google Scholar 

  228. Ilowite NT. Premature atherosclerosis in systemic lupus erythematosus. J Rheumatol Suppl 2000;58:15–19.

    PubMed  CAS  Google Scholar 

  229. Karrar A, Sequeira W, Block JA. Coronary artery disease in systemic lupus erythematosus: A review of the literature. Semin Arthritis Rheum 2001;30(6):436–443.

    Article  PubMed  CAS  Google Scholar 

  230. Salmon JE, Roman MJ. Accelerated atherosclerosis in systemic lupus erythematosus: implications for patient management. Curr Opin Rheumatol 2001;13(5):341–344.

    Article  PubMed  CAS  Google Scholar 

  231. Urowitz M, Gladman D, Bruce I. Atherosclerosis and systemic lupus erythematosus. Curr Rheumatol Rep 2000;2(1):19–23.

    Article  PubMed  CAS  Google Scholar 

  232. Ishikawa S, Segar WE, Gilbert EF, Burkholder PM, Levy JM, Viseskul C. Myocardial infarct in a child with systemic lupus erythematosus. Am J Dis Child (1960). 1978;132(7):696–699.

    PubMed  CAS  Google Scholar 

  233. Aranow C, Ginzler EM. Epidemiology of cardiovascular disease in systemic lupus erythematosus. Lupus 2000;9(3):166–169.

    Article  PubMed  CAS  Google Scholar 

  234. Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med 1975;58(2):243–264.

    Article  PubMed  CAS  Google Scholar 

  235. Ilowite NT, Samuel P, Ginzler E, Jacobson MS. Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 1988;31(7):859–863.

    Article  PubMed  CAS  Google Scholar 

  236. Koike T. Antiphospholipid antibodies in arterial thrombosis. Ann Med 2000;32 Suppl 1:27–31.

    PubMed  CAS  Google Scholar 

  237. Ostrov BE, Min W, Eichenfield AH, Goldsmith DP, Kaplan B, Athreya BH. Hypertension in children with systemic lupus erythematosus. Semin Arthritis Rheum 1989;19(2):90–98.

    Article  PubMed  CAS  Google Scholar 

  238. Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten A, de Faire U et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001;104(16):1887–1893.

    Article  PubMed  CAS  Google Scholar 

  239. of Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349(25):2407–2415.

    Article  Google Scholar 

  240. Montes de Oca MA, Babron MC, Bletry O, Broyer M, Courtecuisse V, Fontaine JL et al. Thrombosis in systemic lupus erythematosus: a French collaborative study. Arch Dis Child 1991;66(6):713–717.

    Article  PubMed  CAS  Google Scholar 

  241. Angles-Cano E, Sultan Y, Clauvel JP. Predisposing factors to thrombosis in systemic lupus erythematosus: possible relation to endothelial cell damage. J Lab Clin Med 1979;94(2):312–323.

    PubMed  CAS  Google Scholar 

  242. Esmon NL, Smirnov MD, Safa O, Esmon CT. Lupus anticoagulants, thrombosis and the protein C system. Haematologica 1999;84(5):446–451.

    PubMed  CAS  Google Scholar 

  243. Galli M, Finazzi G, Norbis F, Marziali S, Marchioli R, Barbui T. The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile. Thromb Haemost 1999;81(5):695–700.

    PubMed  CAS  Google Scholar 

  244. Hasselaar P, Derksen RH, Blokzijl L, Hessing M, Nieuwenhuis HK, Bouma BN et al. Risk factors for thrombosis in lupus patients. Ann Rheum Dis 1989;48(11):933–940.

    Article  PubMed  CAS  Google Scholar 

  245. Male C, Lechner K, Eichinger S, Kyrle PA, Kapiotis S, Wank H et al. Clinical significance of lupus anticoagulants in children. J Pediatr 1999;134(2):199–205.

    Article  PubMed  CAS  Google Scholar 

  246. Qushmaq K, Esdaile J, Devine DV. Thrombosis in systemic lupus erythematosus: the role of antiphospholipid antibody. Arthritis Care Res 1999;12(3):212–219.

    Article  PubMed  CAS  Google Scholar 

  247. Asherson RA, Khamashta MA, Gil A, Vazquez JJ, Chan O, Baguley E et al. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. Am J Med 1989;86(4):391–399.

    Article  PubMed  CAS  Google Scholar 

  248. Appel GB, Williams GS, Meltzer JI, Pirani CL. Renal vein thrombosis, nephrotic syndrome, and systemic lupus erythematosus: an association in four cases. Ann Intern Med 1976;85(3):310–317.

    PubMed  CAS  Google Scholar 

  249. Berden JH. Lupus nephritis. Kidney Int 1997;52(2):538–558.

    Article  PubMed  CAS  Google Scholar 

  250. Cheigh JS, Stenzel KH. End-stage renal disease in systemic lupus erythematosus. Am J Kidney Dis 1993;21(1):2–8.

    PubMed  CAS  Google Scholar 

  251. Bruce IN, Hallett DC, Gladman DD, Urowitz MB. Extrarenal disease activity in systemic lupus erythematosus is not suppressed by chronic renal insufficiency or renal replacement therapy. J Rheumatol 1999;26(7):1490–1494.

    PubMed  CAS  Google Scholar 

  252. Leaker B, Fairley KF, Dowling J, Kincaid-Smith P. Lupus nephritis: clinical and pathological correlation. Q J Med 1987;62(238):163–179.

    PubMed  CAS  Google Scholar 

  253. Nossent HC, Swaak TJ, Berden JH. Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis. Dutch Working Party on SLE. Am J Med 1990;89(2):169–174.

    Article  PubMed  CAS  Google Scholar 

  254. Goss JA, Cole BR, Jendrisak MD, McCullough CS, So SK, Windus DW et al. Renal transplantation for systemic lupus erythematosus and recurrent lupus nephritis. A single-center experience and a review of the literature. Transplantation 1991;52(5):805–810.

    Article  PubMed  CAS  Google Scholar 

  255. Mojcik CF, Klippel JH. End-stage renal disease and systemic lupus erythematosus. Am J Med 1996;101(1):100–107.

    Article  PubMed  CAS  Google Scholar 

  256. Nossent HC, Swaak TJ, Berden JH. Systemic lupus erythematosus after renal transplantation: patient and graft survival and disease activity. The Dutch Working Party on Systemic Lupus Erythematosus. Ann Intern Med 1991;114(3):183–188.

    PubMed  CAS  Google Scholar 

  257. Ward MM. Outcomes of renal transplantation among patients with end-stage renal disease caused by lupus nephritis. Kidney Int 2000;57(5):2136–2143.

    Article  PubMed  CAS  Google Scholar 

  258. Bunnapradist S, Chung P, Peng A, Hong A, Chung P, Lee B et al. Outcomes of renal transplantation for recipients with lupus nephritis: analysis of the Organ Procurement and Transplantation Network database. Transplantation 2006;82(5):612–618.

    Article  PubMed  Google Scholar 

  259. Bartosh SM, Fine RN, Sullivan EK. Outcome after transplantation of young patients with systemic lupus erythematosus: a report of the North American pediatric renal transplant cooperative study. Transplantation 2001;72(5):973–978.

    Article  PubMed  CAS  Google Scholar 

  260. Moroni G, Tantardini F, Gallelli B, Quaglini S, Banfi G, Poli F et al. The long-term prognosis of renal transplantation in patients with lupus nephritis. Am J Kidney Dis 2005;45(5):903–911.

    Article  PubMed  Google Scholar 

  261. Bergstein JM, Wiens C, Fish AJ, Vernier RL, Michael A. A vascular necrosis of bone in systemic lupus erythematosus. J Pediatr 1974;85(1):31–35.

    Article  PubMed  CAS  Google Scholar 

  262. Trapani S, Civinini R, Ermini M, Paci E, Falcini F. Osteoporosis in juvenile systemic lupus erythematosus: a longitudinal study on the effect of steroids on bone mineral density. Rheumatol Int 1998;18(2):45–49.

    Article  PubMed  CAS  Google Scholar 

  263. Balow JE, Boumpas DT, Fessler BJ, Austin HA, 3rd. Management of lupus nephritis. Kidney Int Suppl 1996;53:S88–S92.

    PubMed  CAS  Google Scholar 

  264. McDermott EM, Powell RJ. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann Rheum Dis 1996;55(4):224–229.

    Article  PubMed  CAS  Google Scholar 

  265. Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 1998;41(5):831–837.

    Article  PubMed  CAS  Google Scholar 

  266. Boumpas DT, Austin HA, 3rd, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993;119(5):366–369.

    PubMed  CAS  Google Scholar 

  267. Appenzeller S, Blatyta PF, Costallat LT. Ovarian failure in SLE patients using pulse cyclophosphamide: comparison of different regimes. Rheumatol Int 2008;28(6):567–571.

    Article  PubMed  CAS  Google Scholar 

  268. Katsifis GE, Tzioufas AG. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus 2004;13(9):673–678.

    Article  PubMed  CAS  Google Scholar 

  269. Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2000;9(6):401–405.

    Article  PubMed  CAS  Google Scholar 

  270. Blumenfeld Z. Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy. Minerva endocrinologica 2007;32(1):23–34.

    PubMed  CAS  Google Scholar 

  271. Manger K, Wildt L, Kalden JR, Manger B. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Autoimmun Rev 2006; 5(4):269–272.

    Article  PubMed  CAS  Google Scholar 

  272. Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis and rheumatism 2005;52(9):2761–2767.

    Article  PubMed  CAS  Google Scholar 

  273. Tangnararatchakit K, Tapaneya-Olarn C, Tapaneya-Olarn W. The efficacy of intravenous pulse cyclophosphamide in the treatment of severe lupus nephritis in children. J Med Assoc Thail 1999;82(Suppl 1):S104–S110.

    Google Scholar 

Download references

Authors
  1. Patrick Niaudet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rémi Salomon
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical College of Wisconsin, Wisconsin, USA

    Ellis Avner (Director, Children's Research Institute, CHHS, Associate Dean for Research, Professor of Pediatrics and Physiology) (Director, Children's Research Institute, CHHS, Associate Dean for Research, Professor of Pediatrics and Physiology)

  2. Harvard Medical School, Children's Hospital Boston, 300 Longwood Avenue, Boston, Massachusetts, 02115, USA

    William Harmon (Professor of Pediatrics, Director, Pediatric Nephrology) (Professor of Pediatrics, Director, Pediatric Nephrology)

  3. Service de Néphrologie Pédiatrique Centre de référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA), Hôpital Necker‐Enfants Malades, 149, rue de Sèvres, 75743, Paris Cedex 15, France

    Patrick Niaudet

  4. Department of Pediatrics Wakayama Medical University, Wakayama Medical University Hospital, 641–8510811–1, Kimiidera, Wakayama City, Japan

    Norishige Yoshikawa (Professor and Chair Pediatrician‐in‐Chief) (Professor and Chair Pediatrician‐in‐Chief)

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag Berlin Heidelberg

About this entry

Cite this entry

Niaudet, P., Salomon, R. (2009). Systemic Lupus Erythematosus. In: Avner, E., Harmon, W., Niaudet, P., Yoshikawa, N. (eds) Pediatric Nephrology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-76341-3_47

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-76341-3_47

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-76327-7

  • Online ISBN: 978-3-540-76341-3

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation